Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Expands By 203.7%

SciSparc Ltd. (NASDAQ:SPRC) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 831,500 shares, a growth of 203.7% from the September 15th total of 273,800 shares. Currently, 8.0% of the company’s stock are sold short. Based on an average daily trading volume, of 3,730,000 shares, the short-interest ratio is presently 0.2 days.

SciSparc Price Performance

Shares of SPRC remained flat at $0.22 during mid-day trading on Friday. 196,027 shares of the stock traded hands, compared to its average volume of 1,700,189. SciSparc has a one year low of $0.21 and a one year high of $14.22. The stock has a 50 day moving average of $0.31 and a 200-day moving average of $0.83.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC purchased a new stake in shares of SciSparc Ltd. (NASDAQ:SPRC) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned about 5.59% of SciSparc as of its most recent filing with the Securities and Exchange Commission (SEC). 25.06% of the stock is owned by hedge funds and other institutional investors.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.